RSNA 2024

Road to RSNA 2024: Molecular Imaging Preview
By Will Morton
Theranostics could be cited for speeding in this year’s Road to RSNA. It's only been a few years since a dedicated track in nuclear medicine and molecular imaging was established at the meeting, and the practice already dominates it.
November 21, 2024
Road To Rsna
FAPI-PET/CT superior to FDG-PET/CT in liver cancer patients
By Will Morton
Ga-68 FAPI-PET/CT imaging appears superior to FDG-PET/CT for assessing hepatocellular carcinomas. In a large prospective trial, the approach was more accurate – enough so that it could possibly replace FDG-PET/CT in the future.
November 21, 2024
FAPI-PET/CT improves detection of primary and metastatic breast cancer
By Will Morton
Ga-68 FAPI-PET/CT significantly enhances the detection rate and staging of primary and metastatic breast cancer, demonstrating superior sensitivity and specificity compared with F-18 FDG-PET/CT.
November 21, 2024
Theranostics cost-effective in men with mCRPC
By Will Morton
Using theranostic radionuclides such as Ra-223 or Lu-177 to treat men with metastatic castration-resistant prostate cancer (mCRPC) is more cost-effective in the long term than traditional chemotherapy and radiotherapy, suggests a study in this session.
November 21, 2024
Treatment-related factors enhance PSMA expression
By Will Morton
Certain prostate cancer features on PSMA-PET may be useful in selecting candidates who are more likely to respond to Lu-177 PSMA-617, according to a presentation in this session.
November 21, 2024
F-18 PSMA-DCFPyL and Ga-68 PSMA-11 deemed equivalent
By Will Morton
PET radiopharmaceuticals F-18 PSMA-DCFPyL and a Ga-68 PSMA-11 appear equivalent for determining patient eligibility for prostate cancer treatment with Lu-177 PSMA-617, researchers say.
November 21, 2024
Additional Coverage
2023
2022
2021
2020
2019
AI segments lesions on Ga-68 DOTATATE PET/CT images
By Will Morton
In this session, researchers will present an automated deep-learning AI model that could help clinicians segment rare neuroendocrine tumors on whole-body 3D gallium-68 (Ga-68) DOTATATE PET/CT images.
November 21, 2024
Are Lu-177 PSMA-617 outcomes applicable in a community setting?
By Will Morton
During this session on theranostics, a study suggests that targeted education is needed to support the delivery of Lu-177 PSMA-617 to patients.
November 21, 2024
FES-PET shows promise for staging invasive lobular carcinoma
By Will Morton
A mid-study analysis presented during this session suggests that F-18 fluoroestradiol (FES) PET/CT may detect unsuspected stage IV invasive lobular carcinoma.
November 21, 2024
Dedicated brain PET system shows promise in Alzheimer’s disease imaging
By Will Morton
A high-resolution dedicated brain PET system could augment visual reading in the early diagnosis of dementia, suggests a study in this session.
November 21, 2024
Can AI chatbots answer questions for patients on Lu-177 PSMA-617 therapy?
By Will Morton
In response to common questions from Lu-177 PSMA-617 patients, Gemini provided easy-to-understand answers and ChatGPT-4 demonstrated high accuracy, yet neither AI chatbot provided completely accurate answers to all questions.
November 21, 2024
AI denoising software valuable for amyloid PET/CT studies
By Will Morton
A study in this session suggests that count-poor and noisy amyloid brain PET/CT studies can be rendered clinically useful through AI denoising software.
November 21, 2024
Page 1 of 9
Next Page